Associated Papers
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models.
Herencia-Ropero A et al.
Genome Medicine, 2024
39187844 (PubMed )
Supplement: 13073_2024_1370_MOESM3_ESM.xlsx › SNV
Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK et al.
Nature Genetics, 2014
24413733 (PubMed )
Supplement: NIHMS547859-supplement-1.xlsx › Supplementary_Table_2
Select a paper to view details